Last edition
News about "DUET-UC study"
JNJ-4804 Co-Antibody Shows Promise in Refractory Inflammatory Bowel Disease
Johnson & Johnson (J&J) investigational JNJ-4804 co-antibody shows superior clinical and endoscopic outcomes in refractory Inflammatory Bowel Disease (IBD), supporting phase 3 advancement with dual IL-23 and TNF pathway targeting.
DUET-UC Study | 07/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members